TYRA Profile
Tyra Biosciences, Inc. is an innovative preclinical-stage biopharmaceutical company dedicated to developing advanced therapies aimed at overcoming tumor resistance and improving treatment outcomes for cancer patients. The company is at the forefront of cancer research with a focus on addressing key challenges associated with tumor resistance, which often limits the effectiveness of existing treatments. Tyra's approach leverages cutting-edge technology to target specific genetic and molecular drivers of cancer.
The company's lead product candidate, TYRA-300, is a selective inhibitor targeting the fibroblast growth factor receptor 3 (FGFR3). This novel therapy is designed for the treatment of muscle-invasive bladder cancer, a condition often resistant to conventional therapies. TYRA-300 aims to provide a more effective treatment option for patients by specifically targeting the FGFR3 mutation, which plays a crucial role in the development and progression of this cancer type.
In addition to TYRA-300, Tyra Biosciences is advancing several other promising programs. These include therapies targeting FGFR2 for intrahepatic cholangiocarcinoma, a type of liver cancer, and FGFR3-related achondroplasia, a genetic disorder affecting bone growth. The company is also developing treatments for cancers associated with the REarranged during transfection (RET) kinase and FGFR4, further expanding its portfolio of targeted therapies.
Tyra Biosciences employs its proprietary SNAP platform to accelerate drug development. The SNAP (Structural Navigation and Architecture Platform) enables rapid structural design through iterative molecular SNAPshots, enhancing the company's ability to design and optimize drug candidates efficiently. Founded in 2018 and headquartered in Carlsbad, California, Tyra Biosciences combines its innovative technology with a robust pipeline to advance the development of targeted cancer therapies and address unmet medical needs in oncology.
|
